Cover Image

Response to "Quantitative Prediction of Drug‐Drug Interactions Involving Inhibitory Metabolites by Physiologically Based Pharmacokinetic Models: Is It Worth?"

Saved in:

Bibliographic Details
Main Authors:	IE Templeton (Author), Y Chen (Author), J Mao (Author), J Lin (Author), H Yu (Author), S Peters (Author), M Shebley (Author), MV Varma (Author)
Format:	Book
Published:	Wiley, 2017-04-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Quantitative Prediction of Drug-Drug Interactions Involving Inhibitory Metabolites by Physiologically Based Pharmacokinetic Models: Is it Worth It?
by: M Tod, et al.
Published: (2017)

A Physiologically Based Pharmacokinetic Model of Ketoconazole and Its Metabolites as Drug-Drug Interaction Perpetrators
by: Fatima Zahra Marok, et al.
Published: (2023)

Quantitative prediction of breast cancer resistant protein mediated drug‐drug interactions using physiologically‐based pharmacokinetic modeling
by: Chester Costales, et al.
Published: (2021)

Prediction of Pharmacokinetic Drug–Drug Interactions Involving Anlotinib as a Victim by Using Physiologically Based Pharmacokinetic Modeling
by: Bu F, et al.
Published: (2024)

Physiologically‐based pharmacokinetic pharmacodynamic parent‐metabolite model of edoxaban to predict drug-drug‐disease interactions: M4 contribution
by: Ruijuan Xu, et al.
Published: (2023)

Evaluation of the Drug-Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP‐5862, Using a Physiologically‐Based Pharmacokinetic Modeling Approach
by: Diansong Zhou, et al.
Published: (2019)

Physiologically Based Pharmacokinetic Modeling of Bupropion and Its Metabolites in a CYP2B6 Drug-Drug-Gene Interaction Network
by: Fatima Zahra Marok, et al.
Published: (2021)

Prediction of Drug-Drug-Gene Interaction Scenarios of (<i>E</i>)-Clomiphene and Its Metabolites Using Physiologically Based Pharmacokinetic Modeling
by: Christina Kovar, et al.
Published: (2022)

Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model
by: Caifu Xue, et al.
Published: (2017)

Simultaneously Predicting the Pharmacokinetics of CES1-Metabolized Drugs and Their Metabolites Using Physiologically Based Pharmacokinetic Model in Cirrhosis Subjects
by: Xin Luo, et al.
Published: (2024)

Development of a cystic fibrosis population model for physiologically based pharmacokinetic models: Is it worth it?
by: Eunjin Hong, et al.
Published: (2024)

Physiologically‐based pharmacokinetic modeling for primary metabolites of CYP3A and P‐glycoprotein inhibitors in drug-drug interactions: Should we assume the free drug hypothesis?
by: Shinji Yamazaki, et al.
Published: (2023)

Physiologically‐based pharmacokinetic modeling of prominent oral contraceptive agents and applications in drug-drug interactions
by: Gareth J. Lewis, et al.
Published: (2024)

Physiologically‐based pharmacokinetic model of sparsentan to evaluate drug-drug interaction potential
by: Nikunjkumar K. Patel, et al.
Published: (2024)

Comprehensive Physiologically Based Pharmacokinetic Model to Assess Drug-Drug Interactions of Phenytoin
by: Leyanis Rodriguez-Vera, et al.
Published: (2023)

Response to "Development of a cystic fibrosis population model for physiologically based pharmacokinetic models: Is it worth it?"
by: Magali Amiel
Published: (2024)

Application of Physiologically Based Pharmacokinetic Modeling to Evaluate the Drug-Drug and Drug-Disease Interactions of Apatinib
by: Hongrui Liu, et al.
Published: (2021)

Evaluation of drug-drug interaction potential for pemigatinib using physiologically based pharmacokinetic modeling
by: Tao Ji, et al.
Published: (2022)

Physiologically‐Based Pharmacokinetic Model‐Informed Drug Development for Fenebrutinib: Understanding Complex Drug‐Drug Interactions
by: Yuan Chen, et al.
Published: (2020)

Evaluation of the drug-drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach
by: Michael J. Hanley, et al.
Published: (2024)

Effects of elagolix on the pharmacokinetics of omeprazole and its metabolites in healthy premenopausal women
by: Ahmed Nader, et al.
Published: (2022)

Physiologically based pharmacokinetic modeling of tacrolimus for food-drug and CYP3A drug-drug-gene interaction predictions
by: Helena Leonie Hanae Loer, et al.
Published: (2023)

Potential drug-drug interaction of olverembatinib (HQP1351) using physiologically based pharmacokinetic models
by: Zhiheng Yu, et al.
Published: (2022)

Physiologically based pharmacokinetic modeling of imatinib and N‐desmethyl imatinib for drug-drug interaction predictions
by: Helena Leonie Hanae Loer, et al.
Published: (2024)

A physiologically‐based pharmacokinetic precision dosing approach to manage dasatinib drug-drug interactions
by: Christina Kovar, et al.
Published: (2024)

Prediction of Drug-Drug Interaction Potential of Tegoprazan Using Physiologically Based Pharmacokinetic Modeling and Simulation
by: Deok Yong Yoon, et al.
Published: (2021)

Recommendations for the Design of Clinical Drug-Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically‐Based Pharmacokinetic Model
by: Yuan Chen, et al.
Published: (2019)

Physiologically‐based pharmacokinetic model‐based translation of OATP1B‐mediated drug-drug interactions from coproporphyrin I to probe drugs
by: Tatsuki Mochizuki, et al.
Published: (2022)

Physiologically‐based pharmacokinetic modeling of the drug-drug interaction between ivacaftor and lefamulin in cystic fibrosis patients
by: Magali Amiel, et al.
Published: (2024)

Physiologically based pharmacokinetic modeling of drug-drug interactions between ritonavir‐boosted atazanavir and rifampicin in pregnancy
by: Shakir Atoyebi, et al.
Published: (2024)

Investigating Transporter‐Mediated Drug‐Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin
by: Q Wang, et al.
Published: (2017)

Application of physiologically based pharmacokinetic modeling in predicting drug–drug interactions for sarpogrelate hydrochloride in humans
by: Min JS, et al.
Published: (2016)

Database of Optimized Proteomic Quantitative Methods for Human Drug Disposition‐Related Proteins for Applications in Physiologically Based Pharmacokinetic Modeling
by: M Vrana, et al.
Published: (2017)

Editorial: Pharmacokinetic Evaluation and Modeling of Clinically Significant Drug Metabolites
by: Constantin Mircioiu, et al.
Published: (2021)

Application of physiologically‐based pharmacokinetic model approach to predict pharmacokinetics and drug-drug interaction of rivaroxaban: A case study of rivaroxaban and carbamazepine
by: Lien Thi Ngo, et al.
Published: (2022)

Drug-drug interaction prediction of ziritaxestat using a physiologically based enzyme and transporter pharmacokinetic network interaction model
by: Jeremy Perrier, et al.
Published: (2023)

Application of Physiologically‐Based Pharmacokinetic Modeling to Predict Gastric pH‐Dependent Drug-Drug Interactions for Weak Base Drugs
by: Zhongqi Dong, et al.
Published: (2020)

Involvement of Organic Anion Transporters in the Pharmacokinetics and Drug Interaction of Rosmarinic Acid
by: Yun Ju Kang, et al.
Published: (2021)

Physiologically‐based pharmacokinetic modeling to predict CYP3A4‐mediated drug‐drug interactions of finerenone
by: Thomas Wendl, et al.
Published: (2022)

A physiologically‐based pharmacokinetic/pharmacodynamic modeling approach for drug-drug‐gene interaction evaluation of S‐warfarin with fluconazole
by: Kuo Geng, et al.
Published: (2024)